Navigation Links
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
Date:12/7/2008

ly DU-176b regimens was comparable to that with warfarin (3.0 percent, 3.8 percent and 3.2 percent, respectively). There were no significant differences in the numbers of patients with elevated liver enzymes or bilirubin across all treatment groups. Although the study was not powered to detect efficacy, there were no significant differences in the rates of secondary efficacy endpoints across treatment groups.

About Atrial Fibrillation

Atrial fibrillation is an irregular heartbeat caused when the upper chambers of the heart (the atria) beat inconsistently and rapidly. When this happens, blood can become stagnant near the walls of the atria and form blood clots. These blood clots can break off and travel through the blood stream to the brain where they can plug blood vessels possibly causing a stroke. These clots can also cause damage to other organs in the body by blocking peripheral arteries.

Approximately 90,000 strokes in the U.S. result from atrial fibrillation.(2) Patients with atrial fibrillation have five times higher risk of having a stroke.(3) These patients also tend to have more serious first strokes than those without atrial fibrillation, resulting in higher mortality rates and longer hospital stays.(1)

About DU-176b

DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism. Notably, Daiichi Sankyo has more than 25 years experience conducting research in the area of Factor Xa inhibition and was the first company to test these compounds in humans.

About Daiichi Sankyo

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization t
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015 Harwood Feffer LLP ( www.hfesq.com ) ... of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On April ... results from its first Phase 3 registration trial of ... in the trial, Rhopressa failed to meet its primary ...
(Date:4/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/t2mvbz/endoscopy_global ... "Endoscopy Global Market - Forecast to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769) , , ,The global endoscopy market is ... growing at around 7.0% CAGR from 2014 to ... are aging population, increase in cancer, diabetes, and ...
(Date:4/27/2015)... April 27, 2015 Vermillion, Inc. ... gynecologic disease, announced today it will report ... market close on Monday, May 11, 2015, ... webcast at 4:30pm Eastern.Conference Call & Webcast: ... Pacific Domestic: , 888-556-4997International: , 719-457-2628Conference ID: ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3
... Va., Nov. 10, 2011 Primary healthcare distributors continue ... navigating economic, regulatory and business climate challenges in the ... in the U.S. Healthcare Industry released by the ... the non-profit research foundation of the Healthcare Distribution Management ...
... SKILLMAN, N.J., Nov. 10, 2011 ConvaTec Healthcare today announced that ... 15, 2011. David Johnson, CEO and George Kegler, CFO will host ... telephone. Questions and answers will follow. To participate ... 701-0354. To participate in the conference internationally, dial ...
Cached Medicine Technology:Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 2Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 3Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 4ConvaTec Healthcare Announces 2011 Third Quarter Earnings Call 2
(Date:4/27/2015)... MN (PRWEB) April 27, 2015 Based ... Secura Consultants is one of the few insurance marketing ... in the income and asset protection markets as well ... the industry has afforded Secura Consultants the opportunity to ... to make doing business easier and quicker. , An ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 According to ... and Craniofacial Research), after chronic back pain, TMJ disorders ... resulting in pain and disability. In addition, the report ... percent of the population, costing an estimated 4 billion ... million Americans suffering from seemingly unrelated symptoms such as ...
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... 2015 TayganPoint Consulting Group, a ... announce their sponsorship of Girls on the Run ... on the Run is a youth development program ... The program is delivered through an interactive curriculum ... to develop the whole girl – physically, mentally, ...
(Date:4/27/2015)... New York, NY (PRWEB) April 27, 2015 ... Jimmy Buffett tickets at the Alpine Valley Music ... in the Elkhart, Wisconsin and Albuquerque, New Mexico area ... in their neck of the woods. Buffett will ... News in Wisconsin. His tour stops during the ...
Breaking Medicine News(10 mins):Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2
... and format for its “OneMedForum 2009” finance ... in San Francisco at the Sir Francis ... and disrupters” affecting each of the following ... System and Neurostimulation; Cardiology; Urology and Sexual ...
... Farms, Inc.,(OTC Bulletin Board: USFM), a diversified commercial ... Network (OTCFN), a division of,National Financial Communications Corp. ... The OTCFN Report details US Farms, Inc.,s current ... growth and,management team. Interested parties can download ...
... Genaera Corporation (Nasdaq: GENR ) today announced ... to present at the 2008 RBC Capital Markets Healthcare Conference. ... discussion of obesity, entitled, "Shrinking The Obesity Epidemic," and will ... York on Wednesday, December 11 at 11:00 a.m. ET. , ...
... WASHINGTON, Dec. 4 Stem cells derived from bone marrow ... disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily ... Blood , the official journal of the American Society of ... bullosa is a disorder characterized by extraordinarily fragile skin and ...
... the Nation in Giving as Demand for Nonprofit Services Peaks ... More than half of Coloradans report that they will ... during the economic downturn, according to " Generous Colorado: Why ... which reflects data from surveys conducted October 2008. With demand ...
... Empowerment Fund by purchasing the Green Bracelet at www.simmonsjewelryco.com , ... The Diamond Empowerment Fund (D.E.F.), Hearst Magazines, and ... exclusive "Empowerment for Africa" dinner held at Hearst Tower in ... co-founder Russell Simmons and special guests including ...
Cached Medicine News:Health News: OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 3Health News:Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 3Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 4Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4Health News:On World AIDS Day, Russell Simmons and Special Guests Attended 'Empowerment for Africa' Dinner 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: